Thipprapai Mahasaksiri, Chaninan Kositkuljorn, Tanaporn Anuntrangsee, Poonkiat Suchonwanit
Division of Dermatology, Division of Medication, School of Medication, Ramathibodi Hospital, Mahidol College, Bangkok, Thailand
Correspondence: Poonkiat Suchonwanit
Division of Dermatology, Division of Medication, School of Medication, Ramathibodi Hospital, Mahidol College, 270 Rama VI Street, Ratchathewi, Bangkok, 10400, Thailand
Tel +66 2-2011141
Fax +66 2-201-1211 Ext 4
E mail [email protected]
Summary: Therapy of in depth or recalcitrant alopecia areata (AA) is a significant scientific problem. Even after thorough investigation of a number of medicines, its remedy outcomes have remained unsatisfactory. Whereas there isn’t a US Meals and Drug Administration-approved treatment for AA but, topical immunotherapy has been a well-documented remedy possibility. Dinitrochlorobenzene, squaric acid dibutylester, and diphenylcyclopropenone are three substances which have demonstrated efficacy within the remedy of in depth or recalcitrant AA. Regardless of being generally used, the mechanism underlying topical immunotherapy is just not well-elucidated and a variety of scientific efficacies have been reported within the literature. The intention of this overview was to summarize and replace the pharmacology, mechanism of motion, therapeutic efficacy, and tolerability of topical immunotherapy within the remedy of AA.
Key phrases: contact sensitizers, dinitrochlorobenzene, diphencyprone, diphenylcyclopropenone, hair loss, squaric acid dibutylester
This work is printed and licensed by Dove Medical Press Restricted. The complete phrases of this license can be found at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License.
By accessing the work you hereby settle for the Phrases. Non-commercial makes use of of the work are permitted with none additional permission from Dove Medical Press Restricted, offered the work is correctly attributed. For permission for business use of this work, please see paragraphs 4.2 and 5 of our Terms.